Acid Suppression for Reflux Disease: "Off-the-Peg" or a Tailored Approach?

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 3, 2012, Pages 210-213

  Hunt, Richard ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

AREA UNDER THE CURVE; DISEASE CONTROL; DRUG HALF LIFE; EDITORIAL; GASTRIC PH MONITORING; GASTROESOPHAGEAL REFLUX; HUMAN; MEAN RESIDENCE TIME; MORNING DOSAGE; PATHOPHYSIOLOGY; PATIENT CARE; PRESCRIPTION; TREATMENT RESPONSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MALE; PROTON PUMP INHIBITORS;

EID: 84857193553     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.11.018     Document Type: Editorial

References (39)

1. Fass R., Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009, 58:295-309.
2. Chey W.D., Mody R.R., Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?. Dig Dis Sci 2010, 55:3415-3422.
3. Kahrilas P.J., Shaheen N.J., Vaezi M.F., et al. American Gastroenterological Association: American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008, 135:1383-1391.
4. Chey W.D., Mody R., Chen L., et al. Nighttime symptoms and sleep impairment among patients with gastro-esophageal reflux disease (GERD) receiving prescription (Rx) proton pump inhibitors (PPIs). Gastroenterology 2008, 134(Suppl 1):A323-A324.
5. Targownik L.E., Metge C., Roos L., et al. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol 2007, 102:942-950.
6. Fass R., Inadomi J., Han C., et al. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol 2012, 10:247-253.
7. Coté G.A., Ferreira M.R., Rozenberg-Ben-Dror K., et al. Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. Aliment Pharmacol Ther 2007, 25:709-714.
8. Howden C.W., Kahrilas P.J. Just how "difficult" is it to withdraw PPI treatment?. Am J Gastroenterol 2010, 105:1538-1540.
9. Metz D.C., Vakily M., Dixit T., et al. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009, 29:928-937.
10. Vakily M., Zhang W., Wu J., et al. Pharmacokinetics and pharmaco-dynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009, 25:627-638.
11. Orr W.C. Reflux events and sleep: are we vulnerable?. Curr Gastroenterol Rep 2006, 8:202-207.
12. Peghini P.L., Katz P.O., Bracy N.A., et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998, 93:763-767.
13. Gerson L.B., Triadafilopoulos G., Sahbaie P., et al. Time esophageal pH <4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors. BMC Gastroenterol 2008, 8:15.
14. Wang C.C., Yuan Y., Chen Y., et al. Night-time pH holding time: what is hidden by the % of time pH <4?. Am J Gastroenterol 2008, 103(Suppl 1):S51. no 130.
15. Galmiche J.P., Zerbib F., Bruley des Varannes S. Review article: respiratory manifestations of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008, 27:449-464.
16. Shaker R., Castell D.O., Schoenfeld P.S., et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003, 98:1487-1493.
17. Tytgat G.N. Are there unmet needs in acid suppression?. Best Pract Res Clin Gastroenterol 2004, 18(Suppl):67-72.
18. Wang C., Hunt R.H. Precise role of acid in nonerosive reflux disease. Digestion 2008, 78(Suppl 1):31-41.
19. Dean B.B., Gano A.D., Knight K., et al. Effectiveness of proton pump inhibitors in non-erosive reflux disease. Clin Gastroenterol Hepatol 2004, 2:656-664.
20. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007, 41:131-137.
21. El-Serag H.B. Epidemiology of nonerosive reflux disease. Digestion 2008, 78(Suppl):6-10.
22. Weijenborg P.W., Cremonini F., Smout A.J.P.M., et al. PPI-therapy is as effective in well-defined NERD patients as in patients with reflux esophagitis: a meta-analysis. Gut 2011, 60(Suppl 3):A37.
23. Bell N.J., Burget D., Howden C.W., et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992, 51(Suppl 1):59-67.
24. Howden C.W., Burget D.W., Hunt R.H. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 1994, 201:79-82.
25. Hunt R.H. Importance of pH control in the management of GERD. Arch Intern Med 1999, 159:649-657.
26. Yuan Y., Hunt R.H. Intragastric pH holding time pH <3 at steady state in healthy volunteers (HV) after once daily PPIs: a predictor for low erosive esophagitis (EE) healing rates?. Gastroenterology 2009, 136(Suppl):M1900.
27. Smith J.L., Opekun A.R., Larkai E., et al. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989, 96:683-689.
28. Johnson L.F., Demeester T.R. Twenty-four-hour pH monitoring of the distal esophagus: a quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974, 62:325-332.
29. Ribolsi M., Emerenziani S., Caviglia R., et al. Short duration of acid exposure sensitizes the esophagus to perception of weakly acidic and mixed reflux in nonerosive reflux disease (NERD) patients. Gastroenterology 2008, 134(Suppl 1):A593.
30. Karamanolis G., Vanuytsel T., Sifrim D., et al. Yield of 24-h esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008, 53:2387-2393.
31. Yuan Y., Hunt R.H. Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need?. Am J Gastroenterol 2008, 103(Suppl 1):S50. no 128.
32. Mackalski B.A., Ilnyckyj A. Esophageal pH testing in patients refractory to proton pump inhibitor therapy. Can J Gastroenterol 2008, 22:249-252.
33. Hunt R.H. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 2005, 22(Suppl 3):10-19.
34. Katz P.O., Scheiman J.M., Barkun A.N. Review article: acid-related disease-what are the unmet clinical needs?. Aliment Pharmacol Ther 2006, 23(Suppl 2):9-22.
35. Scarpignato C., Hunt R.H. Proton pump inhibitors: the beginning of the end or the end of the beginning?. Curr Opin Pharmacol 2008, 8:677-684.
36. Sachs G., Shin J.M., Hunt R. Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep 2010, 12:437-447.
37. Vakil N. New pharmacological agents for the treatment of gastroesophageal reflux disease. Rev Gastroenterol Disord 2008, 8:117-122.
38. Hunt R.H., Armstrong D., Yaghoobi M., et al. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008, 28:187-199.
39. Hunt R.H., Armstrong D., James C., et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005, 100:1949-1956.